These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26154926)

  • 21. A Randomized Trial of the Impact of Ferric Citrate on Erythropoietin and Intravenous Iron Use in Patients Receiving Dialysis.
    Block GA; Mizani MR; Broumand V; Newby FD; Erinle A; Arias C; Block M; Brillhart S; Leppink A; Danese M; Dittrich M
    Am J Nephrol; 2024; 55(5):520-528. PubMed ID: 38972306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Supplemental iron via dialysate: a novel mode of delivery for hemodialysis patients.
    Macdougall IC
    Kidney Int; 2015 Nov; 88(5):946-9. PubMed ID: 26579682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Individualized anemia management enhanced by ferric pyrophosphate citrate protocol.
    Chait Y; Nathanson BH; Germain MJ
    Sci Rep; 2022 Nov; 12(1):20122. PubMed ID: 36418453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anemia Management among Hemodialysis Patients with High Ferritin Levels.
    Einbinder Y; Agur T; Davidov K; Zitman-Gal T; Golan E; Benchetrit S
    Isr Med Assoc J; 2018 Jul; 20(7):405-411. PubMed ID: 30109787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study.
    Peters NO; Jay N; Cridlig J; Rostoker G; Frimat L
    BMC Nephrol; 2017 Mar; 18(1):97. PubMed ID: 28320343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
    Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
    J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target.
    Hung SC; Tarng DC
    Kidney Int; 2014 Oct; 86(4):676-8. PubMed ID: 25265951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron.
    Kapoian T
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S21-8. PubMed ID: 19010258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. It's time to compare anemia management strategies in hemodialysis.
    Coyne DW
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial.
    Goldstein SL; Morris D; Warady BA
    Am J Kidney Dis; 2013 Apr; 61(4):588-97. PubMed ID: 23245582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of a change in erythropoiesis-stimulating agent dose during hospitalization and subsequent hemoglobin levels and transfusions in hemodialysis patients.
    Wong BC; Ravani P; Manns BJ; Lewin A; Zhang X; Chin R; Hemmelgarn BR; Tonelli M; Oliver MJ; Quinn RR
    Am J Kidney Dis; 2013 Nov; 62(5):947-52. PubMed ID: 23856380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
    Yong K; Kairaitis L
    Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
    Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
    Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
    Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
    J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changing patterns of anemia management in US hemodialysis patients.
    Freburger JK; Ng LJ; Bradbury BD; Kshirsagar AV; Brookhart MA
    Am J Med; 2012 Sep; 125(9):906-14.e9. PubMed ID: 22938926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.
    Umanath K; Jalal DI; Greco BA; Umeukeje EM; Reisin E; Manley J; Zeig S; Negoi DG; Hiremath AN; Blumenthal SS; Sika M; Niecestro R; Koury MJ; Ma KN; Greene T; Lewis JB; Dwyer JP;
    J Am Soc Nephrol; 2015 Oct; 26(10):2578-87. PubMed ID: 25736045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence.
    Singh A
    Semin Dial; 2009; 22(1):64-9. PubMed ID: 19175537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis.
    Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
    J Ren Nutr; 2014 Jul; 24(4):261-7. PubMed ID: 24836401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial.
    Singh H; Reed J; Noble S; Cangiano JL; Van Wyck DB;
    Clin J Am Soc Nephrol; 2006 May; 1(3):475-82. PubMed ID: 17699248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.